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26 years period was associated with 18,59 LYG. At the same time use of autocoded 
blood glucose meters was associated with 18,92 LYG. In case of using autocoded 
meters instead of using manually coding meters patients obtained 0,33 LYG more 
(120 days). ConClusions: Obtained results showed that difference in glucose 
measurement errors between manually coded and autocoded blood glucose meters 
can lead to the difference in long-term outcomes in diabetes treatment.
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objeCtives: Type 2 diabetes mellitus (T2DM) is a chronic disease associated 
with increased risk of cardiovascular (CV) and microvascular complications. 
Improvements in blood pressure and cholesterol control have resulted in a reduc-
tion in CV event rates in clinical practice. The objective of this study was to assess 
the relationship between increased life expectancy, due to reduction in CV event 
rates, and the risk of microvascular disease for a range of glycemic control lev-
els. Methods: A lifetime analysis was conducted using the CORE diabetes model 
(CDM). Newly diagnosed T2DM simulated patients aged 52 years at baseline with 
HbA1c 7.1%, SBP 135.1 mmHg, total cholesterol: HDL 5.2 mmol/l were modelled. The 
impact of HbA1c on microvascular complications was assessed by running the CDM 
with baseline HbA1c ±1% for scenario 1: 100% of patient receiving CV risk factor 
management; and scenario 2: no CV risk factor management. Results: Improved 
CV risk factor management reduced the predicted cumulative incidence of fatal 
myocardial infarction (MI) from 27% to 18%, increasing life expectancy by an aver-
age of 2 years. For scenario 1, baseline HbA1c +1% versus -1% was associated with 
a 20%, 11% and 4% increase in microalbuminuria (MA), gross proteinuria (GRP) and 
end stage renal disease (ESRD), respectively; for scenario 2, the increase was 15.5% 
for MA, 7.6% for GRP and 2.5% for ESRD. Cumulative incidence of neuropathy ranged 
from 68.4% (baseline HbA1c +1%) to 42.1% (baseline HbA1c -1%) for scenario 1 and 
from 65.2% (baseline HbA1c +1%) to 39.7% (baseline HbA1 c-1%) for scenario 2. 
Cumulative retinopathy rates were similar across both scenarios: 56.7% versus 56.0% 
for scenarios 1 and 2, respectively. ConClusions: This modeling study suggests 
that improvements in blood pressure and cholesterol management may result in 
increased rates of microvascular complications, in particular renal disease, over the 
long term as patient survival increases.
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objeCtives: A significant proportion of patients with type-2-diabetes mellitus 
(T2DM) are unable to take Metformin as recommended first-line therapy due to 
gastrointestinal intolerance or contraindications such as chronic kidney disease. 
In contrast to combination therapy no network meta-analysis (NMA) has been 
undertaken for oral anti-diabetic drugs (OAD) as monotherapy in this population - 
particularly with respect to gliptins and sulfonylureas as second-line options. The 
purpose of this study is to assess the comparative effectiveness and tolerability of 
gliptins versus sulfonylureas in terms of glycated hemoglobin (HbA1c), body weight 
and hypoglycemia. Methods: A systematic review was conducted searching bib-
liographic databases, reports of regulatory authorities and clinical trial registries 
through July 2012 to identify randomized controlled trials in adult T2DM patients 
receiving at least 12 weeks of OAD monotherapy or placebo. A Bayesian NMA was 
performed to yield mixed treatment comparisons. Consistency was examined by the 
node split method. Results: A total of 62 studies enrolling 21,302 patients informed 
the entire network. Due to their improved model fit estimates from random effect 
models are reported to account for heterogeneity across the set of studies. After a 
mean follow-up of 32 weeks, the difference in mean HbA1c was 0.26, 0. 95 credible 
interval (CrI0.95): [0.1; 0.42], in favour of sulfonylureas. However, gliptins induced 
weight loss (difference in means: -1.21 kg; CrI0.95: [-1.57; -0.84] ) and were associated 
with a considerably lower incidence of any hypoglycemia compared to sulfonylureas 
(odds ratio: 0.22; CrI0.95: [0.15; 0.31] ). All effect estimates were statistically significant 
and consistent in terms of combining direct and indirect evidence. ConClusions: 
This is the first network assessing OAD monotherapy that can readily be extended 
to emerging therapies. With regard to glycemic control gliptins were slightly inferior 
to sulfonylureas, whereas they positively affected body weight and risk of hypogly-
cemia, confirming their role in second-line monotherapy.
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objeCtives: Inadequate glycemic, blood pressure (BP), and low-density lipopro-
tein (LDL) control among persons with type 2 diabetes mellitus (T2DM) increases 
the risk of T2DM-related complications, which require more intensive and costly 
therapy. Extending on a recently-conducted study in Dubai, UAE, we assessed levels 
of glycemic, LDL, and BP control, and estimated the proportion of those meeting 
offers similar or reduced HbA1c reduction, had comparable significant weight loss 
to other SLGT-2s and GLP-1s, and appeared to have a superior weight loss profile 
compared with DPP-4s and TZDs.. No increased risk of adverse events were observed 
for empagliflozin compared with placebo and other ADs.
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objeCtives: The aim of the present network meta-analysis is to compare the effi-
cacy and safety of empagliflozin versus other antidiabetic drugs used in third line 
for the treatment of patients with type 2 diabetes mellitus (T2DM). Methods: We 
conducted a systematic review randomized controlled trials (RCTs) and Bayesian 
network meta-analysis to establish the comparative efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s, and TZDs. RCTs enrolling subjects with T2DM inadequately con-
trolled on metformin plus sulfonylurea were included. The principal outcome of 
this analysis was the effect of these drugs on HbA1c, weight, systolic blood pres-
sure (SBP), incidence of hypoglycaemia and urinary tract infections (UTIs) at 24 
weeks. Results: From 6969 abstracts, 13 were included in the analysis. No RCTs 
involving TZDs were identified. Compared with placebo, mean changes in HbA1c 
were -0.65% [95% confidence interval (CI) -1.59 to -0.08%] and -0.60% [95%CI -1.14 to 
-0.14%] for empagliflozin 10mg and 25mg. No significant differences were detected 
between interventions. Mean changes in weight with empagliflozin 10mg and 25mg 
were -1.77 [95%CI -2.19 to -1.35) and -2.00 (95%CI -2.44 to -1.57), respectively. Mean 
weight losses were fairly similar across SLGT-2s and GLP-1s ranging between -1.26 
to -2.12. All DPP-4s were associated weight gains, ranging form 0.33 to 0.98, of which 
most were statistically significant. SBP data were only available for SGLT-2s and 
DPP-4s. Empagliflozin 10mg and 25mg compared with placebo had statistically sig-
nificant reductions of -2.70 and -2.09. All interventions (except exenatide) yielded 
relative risk of hypoglycaemia greater than 1.00. For UTIs, no differences were found 
between SLGT-2s or DPP-4s and placebo. ConClusions: Compared with other 
SGLT-2s, DPP-4s, and GLP-1s, empagliflozin generally offers similar HbA1c control 
at week 24, an advantageous profile in weight loss and reduction of SBP, as well as 
similar safety profile.
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objeCtives: To compare the efficacy and safety of empagliflozin versus other sec-
ond-line treatment for patients with type 2 diabetes mellitus (T2DM). Methods: A 
systematic review and Bayesian network meta-analysis were performed to identify 
randomized controlled trials (RCTs) assessing the efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s, TZDs, and SUs in patients with T2DM. RCTs enrolling subjects with 
T2DM inadequately controlled with metformin monotherapy were included. The 
principal outcomes were HbA1c, weight, systolic blood pressure (SBP), hypoglycae-
mia, and urinary tract infections (UTIs) at 24 weeks. Results: Forty-eight RCTs 
were included. The mean differences (MD) in HbA1c were -0.56% [95% confidence 
interval (CI) -1.06% to -0.08%] and -0.64% [95%CI -1.14 to -0.14%] for Empagliflozin 
10mg and 25mg vs placebo. All other interventions yielded similar reductions and 
no significant differences were detected between interventions. Empagliflozin 10mg 
and 25mg significantly changed patients’ weight by -1.63kg (95%CI -2.66 to -0.64) 
and -2.01kg (95%CI -3.02 to -1.02), versus placebo. Other SLGT-2s had similar MDs, all 
DPP-4s had no change, and GLP-1s fell in between. All SUs and TZDs were associated 
with significant weight gain versus placebo. For SBP, the MDs for Empagliflozin 10mg 
and 25mg versus placebo were -4.09mmHg (95%CI -6.97 to -1.18) and -4.81mmHg 
(95%CI -7.69 to -2.00). No significant differences between Empagliflozin and other 
interventions were detected. Incidence of hypoglycaemia for empagliflozin 10 and 
25 mg relative to placebo was 2.71 [95%CI 0.46 to 11.44] and 1.97 [95%CI 0.23 to 9.57], 
respectively. No significant differences were detected between emplagliflozin and 
other interventions. For UTIs, all yielded relative risks close to 1.00 when compared 
with placebo. ConClusions: Compared with other SGLT-2s, DPP-4s, GLP-1s, TZDs, 
and SUs, empagliflozin offers similar HbA1c control at 24 weeks, a marked reduc-
tion in weight compared with DPP-4s, TZDs, and SUs, and a similar safety profile 
as other interventions.
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objeCtives: To obtain long-term clinical outcomes of using manually coded 
and autocoded blood glucose meters in diabetes treatment in the Russian 
Federation. Methods: The model used in this study analyzed the influence of 
errors in blood glucose measurements (due to using manually or autocoded glu-
cose meters) on the treatment of patients with Type 1 and Type 2 diabetes during 
the 26 years period (the life-time period). Life years gained (LYG) was chosen as an 
outcome measure in assessment of health intervention. Calculation of LYG was 
based on prior clinical studies that evaluated glucose meters’ errors in glucose 
level measurements and risk of complications associated with blood glucose level. 
Data for patients with diabetes was obtained from prior epidemiological studies 
that had been provided in Russian Federation. Results: Use of manually coded 
blood glucose meters in the analyzed population with median age of 53 years during 
